Pharma Icebreaker Panel Discussion: Targeted Oncology Biologics

• Understanding what it takes for pharma to invest. What are the current budgetary considerations within pharma?
• How is pharma assessing novel technologies, and where do they place within portfolios?
• What feels differentiated in a crowded space? From pharma’s perspective, what will make something best-in-class?

Speakers:

Michael Torres

Former - Chief Executive Officer

CrossBridge Bio

Carla Bauer

Director, Oncology Search & Evaluation, Business Development & Licensing

Merck & Co

Matthew Posluszny

Senior Director, Oncology Business Development

AstraZeneca

Anu Connor

Vice President, Head of Oncology Search & Evaluation

Ipsen Pharma

Hong Xin

Executive Director

Johnson & Johnson

Juanjo Cragnolini

Associate Director, Oncology Search & Evaluation

Takeda Pharmaceutical

Xiaodong Zhang

Director of S&E

Novartis AG

Ayano Takeuchi

Scouting and Transaction Lead

Astellas Pharma

Akihiro Furukawa

Global Director, Research & Technology Search & Evaluation

Daiichi Sankyo